Sirtris collaborates with cancer institute

Sirtris Pharmaceuticals Inc. announced today that it will collaborate with the National Cancer Institute to test the anti-cancer impact of its enzyme activators in numerous models of cancer.

Sirtris is a Cambridge biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging.

“By providing the resources for this study, the National Cancer Institute is accelerating the testing of our compounds in both solid and hematological models of cancer,” said Sirtris chief executive Christoph Westphal said in a statement. “Cancer is the second leading cause of age-related mortality, and this study will advance our understanding of SIRT1 activation and its potential anti-cancer properties.”
(By Chris Reidy, Globe staff)